Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Alcohol Clin Exp Res. 2018 Jun 13;42(7):1315–1326. doi: 10.1111/acer.13768

Table 4.

Adverse events reported at baseline and during the course of the study by treatment arm

	Baseline (Pre-treatment)			During study
	Choline	Placebo	t or χ²	Choline	Placebo	t or χ²
Incidence (n (%))
Diarrhea	2 (5.9)	2 (6.1)	0.001	3 (8.8)	5 (15.2)	0.64
Vomiting	7 (20.6)	14 (40.0)	3.07^†	12 (35.3)	8 (22.9)	1.30
Nausea/dyspepsia	15 (44.1)	20 (57.1)	1.17	23 (67.6)	10 (28.6)	10.55**
Muscle stiffness	7 (20.6)	13 (37.1)	2.30	10 (29.4)	17 (48.6)	2.66
Frequency (d/wk)
Diarrhea	0.04 (0.1)	0.1 (0.4)	0.69	0.1 (0.3)	0.2 (0.7)	0.92
Vomiting	0.8 (2.1)	1.5 (2.5)	1.24	0.3 (0.6)	0.2 (0.6)	0.38
Nausea/dyspepsia	1.8 (2.8)	2.4 (3.0)	0.82	0.3 (0.5)	0.1 (0.2)	2.33^*
Muscle stiffness	0.5 (1.4)	1.4 (2.5)	1.70^†	0.03 (0.1)	0.1 (0.1)	1.37
MAP (mmHg)	80.6 (9.4)	84.8 (9.4)	1.85^†	81.0 (8.9)	85.1 (0.1)	1.84^†

MAP = mean arterial pressure

^†

p < 0.10

^*

p < 0.05